par Awada, Ahmad 
;Thödtmann, R;Piccart-Gebhart, Martine ;Wanders, Jantien;Schrijvers, A H G J;Von Broen, I-M;Hanauske, Axel-R;EORTC-ECSG phase I study,
Référence European journal of cancer, 39, 6, page (742-747)
Publication Publié, 2003-04
;Thödtmann, R;Piccart-Gebhart, Martine ;Wanders, Jantien;Schrijvers, A H G J;Von Broen, I-M;Hanauske, Axel-R;EORTC-ECSG phase I study, Référence European journal of cancer, 39, 6, page (742-747)
Publication Publié, 2003-04
Article révisé par les pairs
| Titre: |
|
| Auteur: | Awada, Ahmad; Thödtmann, R; Piccart-Gebhart, Martine; Wanders, Jantien; Schrijvers, A H G J; Von Broen, I-M; Hanauske, Axel-R; EORTC-ECSG phase I study, |
| Informations sur la publication: | European journal of cancer, 39, 6, page (742-747) |
| Statut de publication: | Publié, 2003-04 |
| Sujet CREF: | Sciences bio-médicales et agricoles |
| MeSH keywords: | Adult |
| Aged | |
| Amides -- administration & dosage | |
| Amides -- adverse effects | |
| Amides -- pharmacokinetics | |
| Antineoplastic Agents -- administration & dosage | |
| Antineoplastic Agents -- adverse effects | |
| Antineoplastic Agents -- pharmacokinetics | |
| Cohort Studies | |
| Drug Administration Schedule | |
| Female | |
| Half-Life | |
| Humans | |
| Infusions, Intravenous | |
| Isoquinolines -- administration & dosage | |
| Isoquinolines -- adverse effects | |
| Isoquinolines -- pharmacokinetics | |
| Male | |
| Maximum Tolerated Dose | |
| Middle Aged | |
| Neoplasms -- drug therapy | |
| Note générale: | Clinical Trial |
| Clinical Trial, Phase I | |
| Journal Article | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0959-8049 |
| info:pii/S0959804902007761 | |
| info:pmid/12651198 |
